Rochester Electronics Partners with SkyHigh Memory Ltd.
15.8.2023 16:00:00 EEST | Business Wire | Press release
Rochester Electronics, LLC has joined forces with SkyHigh Memory Ltd. to provide a continued source of supply for low-density, mature NAND storage solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230815306980/en/
Rochester Electronics Partners with SkyHigh Memory Ltd. (Graphic: Business Wire)
The collaboration between Rochester Electronics and SkyHigh Memory is powerful. Rochester Electronics focuses on 100% authorized legacy and end-of-life (EOL) semiconductor technologies, while SkyHigh Memory specializes in NAND storage solutions in SLC and eMMC. With those combined talents, they aim to support customers' storage needs worldwide.
EOL microprocessors within existing designs may continue to require storage solutions with low-density capabilities, which perfectly complement SkyHigh Memory’s SLC NAND products ranging from 1Gb to 8Gb and 4GB eMMC. These mature densities can be supported by Rochester’s core microprocessor components’ lifecycles. Rochester Electronics stocks an extensive portfolio of processors, including continued production of numerous legacy and EOL processors through licensing, die banks, and die product replications.
“Our partnership with SkyHigh Memory bolsters Rochester Electronics’ customer base and offerings with a continuity of supply in low-density mature NAND storage solutions. Memory longevity is achieved alongside legacy microprocessor technology.” – Paul Mason, Global Director Memory Technology Rochester Electronics.
“Rochester Electronics’ strengths in managing and supporting legacy and EOL devices, particularly in the realm of microprocessors align with SkyHigh Memory’s mature SLC NAND and eMMC storage solutions. By partnering together, we can offer our customers seamless continuity for their NAND storage needs.” – Alexander Stempfle, Director, Supplier Development – EMEA Rochester Electronics
“We are looking forward to a strong partnership with Rochester Electronics in order to increase the service provided to our customers globally.” - Yildirim Vural, Sales Director – Central & Eastern Europe
About Rochester Electronics
Rochester Electronics is the world’s largest continuous source of semiconductors–100% Authorized by over 70 leading semiconductor manufacturers.
As an original manufacturer stocking distributor, Rochester has over 15 billion devices in stock encompassing more than 200,000-part numbers, providing the world’s most extensive range of end-of-life (EOL) semiconductors and the broadest range of active semiconductors.
As a licensed semiconductor manufacturer, Rochester has manufactured over 20,000 device types. With over 12 billion die in stock, Rochester has the capability to manufacture over 70,000 device types. Rochester offers a full range of manufacturing services including Design, Wafer Processing, Assembly, Test, Reliability, and IP Archiving, providing single solutions through to full turnkey manufacturing, enabling faster time-to-market.
Rochester is the Semiconductor Lifecycle Solution. No other company compares to the breadth of Rochester’s product selection, value-added services, and manufacturing solutions.
With direct sales and support staff in all major markets, complemented by a network of regional and global authorized channel partners, we aim to meet your needs over the phone or via our e-commerce platforms anytime, anywhere.
For more information visit: www.rocelec.com
About SkyHigh Memory
Founded in 2019, SkyHigh Memory is the leader in advanced embedded system solutions for the world's most innovative automotive, industrial, home automation and appliances, consumer electronics, and medical products. SkyHigh Memory reliable, high-performance memories help engineers design differentiated products and get them to market first. SkyHigh Memory is committed to providing customers with the best support and engineering resources, enabling innovators and out-of-the-box thinkers to disrupt markets and create new product categories in record time.
To learn more, go to www.SkyHighMemory.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230815306980/en/
Contact information
Rochester Electronics, LLC
Director, Global Marketing: Tracey Corbitt
Email: tcorbitt@rocelec.com
SkyHigh Memory Ltd.
Sales Director – Central & Eastern Europe: Vural Yildirim
Email: vural.yildirim@skyhighmemory.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release
ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release
BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin
IHS Towers Publishes 2025 Sustainability Report26.5.2026 13:34:00 EEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom